<DOC>
	<DOCNO>NCT02310490</DOCNO>
	<brief_summary>Study DA-13-007 randomize , evaluator-blinded , within subject ( split face ) multicenter clinical study DermaVeil ( Injectable poly-l-lactic acid ) compare SCULPTRA treatment nasolabial fold wrinkle . Qualifying subject randomize receive DermaVeil SCULPTRA either right leave side face .</brief_summary>
	<brief_title>DermaVeil Versus Sculptra Treatment Nasolabial Folds Wrinkles</brief_title>
	<detailed_description>A randomized , evaluator-blinded , within subject ( split face ) multicenter clinical study DermaVeil ( Injectable poly-l-lactic acid ) compare SCULPTRA treatment nasolabial fold wrinkle . Qualifying subject randomize receive DermaVeil SCULPTRA either right leave side face . The treatment phase consist one three visit 3 week interval eligible subject receive bilateral injection study material leave right nasolabial fold wrinkle , include visit week 3 6 touch ups need . The follow-up phase consist assessment 1 , 3 , 6 , 12 month last treatment , safety efficacy evaluation additional 12 month . Standardized photograph take screen treatment phase follow-up visit . Efficacy evaluation make on-site blinded evaluator , photograph use validate , standardize photo-numeric scale . The primary efficacy comparison study treatment make mean change baseline Wrinkle Severity Rating Scale nasolabial fold ( determine on-site blinded evaluator ) 12 month time point . Study participant continue follow safety efficacy month 18 24 last injection session .</detailed_description>
	<mesh_term>Atrophy</mesh_term>
	<mesh_term>Mannitol</mesh_term>
	<criteria>1 . Outpatient , male female subject race 21 year old . Female subject childbearing potential must negative urine pregnancy test result Baseline Visit ( test must sensitivity least 50U/mL human chorionic gonadotropin ) practice reliable method contraception throughout study . 1 . A female consider childbearing potential unless postmenopausal least 12 month prior study drug administration ; without uterus and/or ovary ; surgically sterile least 6 month prior study drug administration . 2 . Reliable method contraception : hormonal method intrauterine device use &gt; 30 day prior study drug administration ; barrier method plus spermicide use least 14 day prior study drug administration vasectomize partner least 3 month post operative zero sperm count post operatively 2 . Demonstrate clinical evidence moderate severe bilateral age nasolabial area , wrinkle classify grade 3 grade 4 5grade WSRS . 3 . Committed abstain procedure interfere treatment outcome ( exclusion criterion ) throughout study . 4 . Able understand requirement study sign Informed Consent Photography Release form . 1 . Pregnant ( positive urine pregnancy test ) , plan become pregnant study period , infant breastfeeding , childbearing potential practicing reliable method birth control . 2 . Subjects plan facial cosmetic procedure study period prior cosmetic procedure ( i.e. , surgery ) visible scar may affect evaluation response and/or quality photography . 3 . Facial asymmetry , ptosis , excessive dermatochalasis , deep dermal scarring , thick sebaceous skin , inability substantially lessen upper facial rhytids even physically spread apart . 4 . Active skin disease within treatment area within 6 month prior study entry . 5 . History malignancy , exclude nonmelanoma skin cancer within past 5 year . 6 . Profound atrophy/excessive weakness muscle target area injection . 7 . History facial nerve palsy . 8 . Facial wrinkle therapy , permanent endure dermal filler previous 2 year bioresorbable previous 12 month . 9 . Allergy sensitivity component study medication ( Section 8.1 ) , know sensitivity local anesthetic . 10 . Previous botulinum toxin therapy within six ( 6 ) month Baseline Visit . 11 . Use systemic prednisone , penicillamine , anti metabolite bioequivalent collagen production inhibitor within 3 month Baseline Visit . 12 . Has receive ( plan receive ) anticoagulation , antiplatelet , thrombolytic medication ( e.g. , warfarin ) , antiinflammatory drug ( oral/injectable corticosteroid nonsteroidal anti inflammatory , eg. , aspirin , ibuprofen ) , substance know increase coagulation time ( e.g. , Vitamin E , garlic , gingko ) . To clarify , nonsteroidal anti inflammatory e.g . asprin ibuprofen within 10 day prior injection 3 day post injection . 13 . Evidence recent alcohol drug abuse . 14 . Medical and/or psychiatric problem , Investigator 's opinion , severe enough interfere study result . 15 . History poor cooperation , noncompliance medical treatment , unreliability . 16 . Participation investigational drug investigational device study within 3 month Baseline Visit . 17 . A history connective tissue disease ( rheumatoid Arthritis , arthritis , lupus ) . 18 . A history multiple severe allergy history anaphylactic shock . 19 . Patients known history susceptibility keloid formation hypertrophic scarring .</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Nasolabial Folds</keyword>
</DOC>